Caribou Biosciences, Inc. (NASDAQ:CRBU) CEO Rachel E. Haurwitz Acquires 20,000 Shares

Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) CEO Rachel E. Haurwitz acquired 20,000 shares of the stock in a transaction on Friday, March 14th. The stock was bought at an average cost of $1.02 per share, for a total transaction of $20,400.00. Following the transaction, the chief executive officer now owns 3,369,395 shares of the company's stock, valued at approximately $3,436,782.90. This trade represents a 0.60 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.Get Caribou Biosciences alerts:Caribou Biosciences Trading Up 0.5 %MarketBeat Week in Review – 7/10 - 7/14Shares of CRBU traded up $0.01 during mid-day trading on Monday, reaching $1.02. The company's stock had a trading volume of 83,205 shares, compared to its average volume of 1,603,439. The stock has a market cap of $94.40 million, a PE ratio of -0.62 and a beta of 2.34. Caribou Biosciences, Inc. has a 52 week low of $0.98 and a 52 week high of $5.77. The company's fifty day moving average price is $1.37 and its two-hundred day moving average price is $1.77. Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.01. The firm had revenue of $2.08 million during the quarter, compared to analyst estimates of $2.11 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. Research analysts anticipate that Caribou Biosciences, Inc. will post -1.64 EPS for the current year. Institutional Inflows and Outflows3 Biotech Stocks to Buy for Long-Term GainsInstitutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its position in shares of Caribou Biosciences by 475.9% in the 4th quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company's stock worth $3,969,000 after buying an additional 2,062,563 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Caribou Biosciences in the 4th quarter worth about $1,921,000. Schonfeld Strategic Advisors LLC grew its position in shares of Caribou Biosciences by 28.4% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company's stock worth $3,360,000 after buying an additional 467,738 shares during the period. Two Sigma Advisers LP grew its position in Caribou Biosciences by 39.5% during the 4th quarter. Two Sigma Advisers LP now owns 1,470,700 shares of the company's stock valued at $2,338,000 after purchasing an additional 416,600 shares during the last quarter. Finally, Ameriprise Financial Inc. purchased a new stake in Caribou Biosciences during the 4th quarter valued at about $649,000. 77.51% of the stock is currently owned by institutional investors. Wall Street Analysts Forecast GrowthSeveral analysts have commented on the stock. Citigroup lowered their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a "buy" rating on the stock in a research report on Tuesday, November 26th. Bank of America reduced their target price on shares of Caribou Biosciences from $13.00 to $11.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Caribou Biosciences has an average rating of "Buy" and an average target price of $10.33.Pfizer Just Invested $25 million In This BiotechView Our Latest Stock Analysis on CRBUCaribou Biosciences Company Profile (Get Free Report)Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.Featured StoriesFive stocks we like better than Caribou BiosciencesMost active stocks: Dollar volume vs share volumeConsumers Are Cutting Back, But These 3 Stocks Will Stay StrongAsset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?Disney Stock: 4 Key Metrics Validating Its ComebackCanadian Penny Stocks: Can They Make You Rich? Resilient Investing: 3 Stocks Built to Weather Market VolatilityThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Caribou Biosciences Right Now?Before you consider Caribou Biosciences, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Caribou Biosciences wasn't on the list.While Caribou Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here